ClinicalTrials.gg
RecruitingNCT07514962MINOTAURUpdated Apr 14, 2026

Minimally Invasive Coronary Artery Bypass Supported by Cangrelor

An observational study in Coronary Artery Disease, Antiplatelet Therapy and Minimally Invasive Coronary Revascularization Surgery, sponsored by Cardiocentro Ticino. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by Cardiocentro Ticino · Observational

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Other
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 177 studies in Coronary Artery Disease with a site in Switzerland — 31 open to participants now, 41 under way, 4 of them phase 3. Coronary Artery Disease · Switzerland.

Planned enrollment
47th of 52
30 · median 992
Started
2024
with 5 others
Observational
52 of 177
15 open now
Primary completion
2028-01
later than 21 of 40 live
Registered
173rd of 177
by date
Lead sponsor
4 of 177
Cardiocentro Ticino

Among the 177 studies in Coronary Artery Disease with a site in Switzerland, this one is the 47th largest by planned enrollment of the 52 observational ones that give a count, is one of 6 that started in 2024, is one of 52 observational ones, reaches primary completion later than 21 of the 40 other live ones, and was the 173rd registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

31 of the 177 studies in Coronary Artery Disease with a site in Switzerland are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 177 studies in Coronary Artery Disease with a site in Switzerland, or all of them as a file.
02

Study summary

The purpose of this study is to find out whether it is safe and practical to perform MIDCAB surgery (a minimally invasive heart bypass procedure) while patients receive a continuous cangrelor infusion during the operation. Cangrelor is a medicine that helps prevent blood clots and works quickly through a vein drip.

The study compares patients receiving cangrelor during surgery to patients who had the same surgery in the past while on aspirin, with or without cangrelor given beforehand.

Study Question: Can MIDCAB surgery be safely performed under cangrelor infusion, without increasing the risk of bleeding or other complications?

Hypothesis: Using cangrelor during MIDCAB surgery is safe and feasible, and it provides effective protection against blood clots during the procedure.

This study will help doctors understand whether intraoperative cangrelor can improve patient safety and outcomes in minimally invasive heart surgery.

Read the detailed description

Study Design Overview The MINOTAUR study is an open-label, single-center, case-control study assessing patients undergoing MIDCAB surgery under continuous cangrelor infusion at 0.75 μg/kg/min compared with historical controls who underwent the same procedure under aspirin therapy with or without prior cangrelor bridging. The study is exploratory and aims to evaluate safety, feasibility, and procedural aspects of intraoperative cangrelor use.

Prospective Arm: Study Intervention and Procedures

Cangrelor Administration: Prior oral antiplatelet therapies are discontinued. Cangrelor infusion is initiated based on daily platelet function testing (Multiplate®) to achieve adequate platelet inhibition before surgery.

Surgical Procedure: MIDCAB is performed ≥24 hours after cangrelor initiation, with intraoperative anticoagulation using unfractionated heparin monitored by activated clotting time.

Perioperative Monitoring: Includes daily assessment of platelet function, vital signs, ECG parameters, cardiac biomarkers (high-sensitivity troponin), and laboratory chemistry.

Data Collection: Procedural details, transfusion requirements, chest tube outputs, ICU stay, and other relevant perioperative variables are recorded in the study database.

Registry Procedures and Quality Assurance

Electronic Data Capture (EDC): All study data are entered into a secure, validated EDC system with role-based access control, audit trails, and SSL encryption. Retrospective alterations are logged in an audit table including time, user, and field changes.

Data Validation: The EDC system performs automated checks for completeness, range, and internal consistency. Central review and periodic cross-checks with source documents ensure data accuracy.

Source Data Verification: Selected data points are verified against medical records, electronic case report forms, operative reports, and lab results to ensure completeness and representativeness.

Data Dictionary: All variables are defined with source, coding standards (e.g., MedDRA, WHO Drug Dictionary), normal ranges, and units.

Standard Operating Procedures (SOPs): SOPs govern patient recruitment, data collection, data management, adverse event reporting, change management, and analytical procedures.

Audit and Monitoring: On-site monitoring is conducted according to a predefined plan, including verification of informed consent, study drug accountability, and completeness of data capture. Third-party auditing may be performed as required.

Sample Size Assessment: Approximately 30 prospective patients are targeted. No formal sample size calculation is required due to the exploratory nature; analyses are primarily descriptive.

Plan for Missing Data: Any missing, unavailable, or inconsistent data are flagged in the EDC and addressed according to predefined rules to avoid bias in analyses.

Safety Monitoring and Reporting

SAEs and ADRs: Only serious adverse events and adverse drug reactions are reported per local regulations; expected and anticipated events are predefined (e.g., bleeding, cardiac complications, acute kidney injury).

Follow-Up: Participants are monitored from inclusion through discharge. Ongoing SAEs are followed until resolution or stabilization.

Regulatory Reporting: Endpoint-related events are reported to the Ethics Committee/IRB and regulatory authorities according to timelines defined by local regulations (e.g., BASEC in Switzerland).

Statistical Analysis Plan

Continuous variables will be analyzed using t-tests or Mann-Whitney tests, depending on normality.

Categorical variables will be compared using Fisher's exact test. Analyses are exploratory and descriptive, comparing prospective cangrelor patients to historical controls.

No formal hypothesis testing is prespecified; data will inform future studies.

Data Handling and Archiving

Confidentiality: Patient data are stored securely, with restricted access. Archiving: The database, trial master file, and reports are retained electronically and in hard copy for ≥10 years.

Data Extraction: Interim and final analyses will use extracted datasets with full audit trail records.

Conclusion The MINOTAUR study is designed to provide technical and quality-controlled data on MIDCAB surgery under cangrelor infusion, with robust procedures for safety monitoring, data validation, and registry management. Findings will inform the feasibility and safety of perioperative intravenous P2Y12 inhibition for minimally invasive coronary bypass procedures.

03

Conditions studied

  • Coronary Artery Disease
  • Antiplatelet Therapy
  • Minimally Invasive Coronary Revascularization Surgery

Keywords

  • Minimally Invasive Direct Coronary Artery Bypass
  • MIDCAB Surgery
  • Coronary Artery Disease
  • Cangrelor
  • Perioperative Antiplatelet Therapy
  • Platelet Function Monitoring
  • Bridging Therapy
  • Cardiac Surgery
  • Intraoperative Antiplatelet Management
  • Bleeding Risk
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population includes adult patients scheduled for minimally invasive direct coronary artery bypass (MIDCAB) surgery at Cardiocentro Ticino Institute, Lugano, Switzerland. Patients will be selected for either prospective cangrelor-guided MIDCAB or retrospective historical control MIDCAB under aspirin therapy. The population includes individuals with multivessel coronary artery disease requiring LIMA-LAD bypass, regardless of sex or comorbidities, who meet all inclusion and no exclusion criteria. Patients with planned concomitant PCI are excluded. This population represents real-world candidates for MIDCAB surgery under antiplatelet management protocols.

Eligibility criteria

Inclusion Criteria for the historical control arm:

  • Age ≥18 years old
  • CABG with IMA-LAD graft in MIDCAB technique

Inclusion criteria for the prospective arm:

  • Age ≥18 years old
  • CABG with IMA-LAD graft in MIDCAB technique
  • Signed

Exclusion criteria for the historical control arm

  • Administration of fibrinolytics or GP IIb/IIIa inhibitors
  • Previous intracranial hemorrhage
  • Known bleeding diathesis
  • Patients undergoing concomitant PCI and MIDCAB
  • Severe renal or liver disease
  • Pregnancy or breast feeding

Exclusion criteria for the prospective arm

  • Unconsciousness
  • Known to study drug (cangrelor)
  • Recent administration of fibrinolytics or GP IIb/IIIa inhibitors
  • Previous intracranial hemorrhage
  • Known bleeding diathesis
  • Patients undergoing concomitant PCI and MIDCAB
  • Severe renal or liver disease
  • Pregnancy or breast feeding
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Case-control
Time perspective
Other
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cangrelor MIDCAB Group (Prospective Cases)

    Patients prospectively enrolled to undergo MIDCAB surgery while receiving continuous cangrelor infusion at 0.75 μg/kg per minute. All prior oral antiplatelet therapy is discontinued, and platelet function is monitored daily with Multiplate® testing. Data collected include perioperative safety, bleeding outcomes, laboratory values, and clinical events.

    Procedure: Cangrelor-guided MIDCAB surgery (for the prospective cases)

  • Aspirin MIDCAB Group (Historical Controls)

    Retrospective patients who previously underwent MIDCAB surgery under aspirin therapy, with or without prior bridging with cangrelor. Relevant perioperative and clinical data are extracted from the institutional database for comparison with the prospective cases.

    Procedure: Aspirin MIDCAB surgery (for the historical controls)

Interventions

  • ProcedureCangrelor-guided MIDCAB surgery (for the prospective cases)

    Cangrelor-guided MIDCAB surgery: Patients undergo minimally invasive direct coronary artery bypass (MIDCAB) with continuous intravenous cangrelor infusion at 0.75 μg/kg per minute. Prior oral antiplatelet therapy is discontinued, and platelet function is monitored daily using Multiplate® testing. Cangrelor infusion is started when platelet aggregation reaches predefined thresholds and continued throughout surgery until it is safe to restart oral antiplatelet therapy.

  • ProcedureAspirin MIDCAB surgery (for the historical controls)

    Aspirin MIDCAB surgery: Historical control patients underwent MIDCAB under aspirin therapy, with or without prior bridging with cangrelor. Perioperative management follows standard care, including anticoagulation with unfractionated heparin during surgery and routine monitoring of laboratory and clinical outcomes.

06

What researchers measure

Primary outcomes

  1. Excessive CABG-related bleeding during and after MIDCAB surgery

    Excessive bleeding is defined as the occurrence of at least one of the following: (1) bleeding requiring surgical re-exploration, (2) 24-hour chest tube output greater than 1 liter, or (3) transfusion of more than 4 units of packed red blood cells. This measure assesses the safety of cangrelor-guided MIDCAB compared with historical aspirin-treated controls.

    Time frame: From the start of surgery through 24 hours postoperatively

Secondary outcomes

  1. In-hospital MACCE

    Occurrence of all-cause death, myocardial infarction, stroke, or urgent revascularization; each component assessed separately.

    Time frame: From surgery through hospital discharge, an average of 8 days

  2. Probable or Defined Stent Thrombosis

    Incidence of stent thrombosis confirmed by angiography or clinical criteria (probable or definite).

    Time frame: From surgery through hospital discharge, an average of 8 days

  3. Cardiac Injury (High-Sensitivity Troponin)

    Daily measurement of high-sensitivity troponin before and after MIDCAB to assess perioperative myocardial injury.

    Time frame: Preoperative baseline until hospital discharge, an average of 10 days

  4. Chest Tube Output

    Volume of postoperative chest drainage measured at 6, 12, 24, and 48 hours after surgery.

    Time frame: 6, 12, 24, and 48 hours postoperatively

  5. Blood Transfusion Requirements and Nadir Hemoglobin

    Number of packed red blood cell units transfused and lowest hemoglobin level recorded, corrected for transfusions.

    Time frame: From surgery through hospital discharge, an average of 8 days

  6. ICU Length of Stay and Mechanical Ventilation Duration

    Duration of stay in intensive care and total hours of mechanical ventilation postoperatively.

    Time frame: From ICU admission post-surgery to ICU discharge, an average of 12-24 hours

  7. BARC-4 Bleeding and Universal Definition of Perioperative Bleeding

    Bleeding severity assessed using BARC-4 criteria and the Universal Definition for Perioperative Bleeding (UDPB).

    Time frame: From surgery through hospital discharge, an average of 8 days

  8. Acute Kidney Injury and Renal Replacement Therapy

    Incidence of acute kidney injury (creatinine increase ≥0.3 mg/dl or ≥1.5x baseline, or urine output \<0.5 ml/kg/h for ≥6h) and need for renal replacement therapy.

    Time frame: From surgery through hospital discharge, an average of 8 days

  9. Length of Hospital Stay

    Total duration of hospitalization from surgery to discharge.

    Time frame: From Surgery to hospital discharge, an average of 10 days

  10. Platelet Function Under Cangrelor Infusion

    Daily platelet function testing (Multiplate®) measuring ADP and arachidonic acid pathways during cangrelor infusion.

    Time frame: From initiation of cangrelor infusion until hospital discharge, an average of 10 days

  11. Vital Signs and 12-lead ECG Parameters

    Monitoring of heart rate (HR, bpm), blood pressure (mmHg), and ECG parameters (PR, QRS, QTc in ms) during hospital stay.

    Time frame: From surgery through hospital discharge, an average of 8 days

  12. Standard Hematology and Blood Chemistry

    Routine hematology assessments including complete blood count (CBC) parameters (e.g., hemoglobin \[g/dL\], hematocrit \[%\], white blood cell count \[×10⁹/L\], platelet count \[×10⁹/L\]). Routine blood chemistry assessments including electrolytes (e.g., sodium \[mmol/L\], potassium \[mmol/L\]), liver function tests (e.g., ALT \[U/L\], AST \[U/L\], bilirubin \[µmol/L\]), kidney function tests (e.g., creatinine \[µmol/L\], urea \[mmol/L\]), and other relevant chemistry parameters, each reported in their respective units of measure.

    Time frame: Preoperative baseline through hospital discharge, an average of 10 days

Other outcomes

  1. Serious Adverse Events and Adverse Drug Reactions

    Any untoward medical occurrence during the study that meets criteria for a Serious Adverse Event (death, life-threatening event, hospitalization, permanent impairment, or medical/surgical intervention to prevent permanent damage) or an Adverse Drug Reaction related to cangrelor infusion. Expected ADRs include bleeding, cardiac tamponade, acute kidney injury, hypersensitivity, dyspnea, or fructose intolerance. Other adverse events are monitored and recorded per protocol.

    Time frame: From study inclusion through hospital discharge or resolution of ongoing events, an average of 10 days

07

Study locations

1 of 1 sites recruiting
  • Istituto Cardiocentro Ticino
    Lugano, Ch/ti 6900, Switzerland
    Recruiting
    • Servizio di Ricerca Cardiovascolare · Contactsrc.ICCT@eoc.ch · +41 (0) 91 811 5055
    • Istituto Cardiocentro Ticino · Contact+41 (0) 91 811 5055
    • Marco Valgimigli, Prof. Dr. Med. · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Jan 2028, 43 months after the start.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 43 months is below that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2026
First posted
Apr 7, 2026
StartActual
May 12, 2024
Primary completionEst.
Jan 1, 2028
CompletionEst.
Jan 1, 2028
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07514962
Lead sponsor
Cardiocentro Ticino
Responsible party
Marco Valgimigli (Cardiology Chief Prof. Dr. Med, Cardiocentro Ticino) — Principal investigator
First posted
Apr 7, 2026
Start date
May 12, 2024
Primary completion
Jan 1, 2028 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Apr 14, 2026

Study contacts

Marco Valgimigli, Prof Dr Med
Contact
marco.valgimigli@eoc.ch
+41 91 811 51 11
Servizio di Ricerca Cardiovascolare Cardiocentro
Contact
enrico.frigoli@eoc.ch
+41 (0)91 811 53 04
Marco Valgimigli, Prof. Dr. Med.
principal investigator · Cardiocentro Ticino

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion